Ratio of Paricalcitol Dosage to Serum Parathyroid Hormone Level and Survival in Maintenance Hemodialysis Patients
Authors:
- Joel D. KoppleJKJoel D. Kopple
- Csaba P. KovesdyCKCsaba P. Kovesdy
- Charles J. McAllisterCMCharles J. McAllister
- David van WyckDWDavid van Wyck
- Sander GreenlandSGSander Greenland
- Kamyar Kalantar-ZadehKamyar Kalantar-Zadeh
Open Access
- 1 November 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 3 (6) , 1769-1776
Abstract
Background and objectives: Several observational studies have indicated that vitamin D receptor activators (VDRA), including paricalcitol, are associated with greater survival in maintenance hemodialysis (MHD) patients; however, patients with higher serum parathyroid hormone (PTH), indicative of a more severe secondary hyperparathyroidism and higher death risk, are usually given higher VDRA dosages, which can lead to confounding by medical indication and attenuated survival advantage of high VDRA dosages. It was hypothesized that the ratio of the administered paricalcitol dosage to serum PTH level discloses better the underlying dosage–survival association. Design, setting, participants, & measurements: The 3-yr mortality predictability of the administered paricalcitol during the first 3 mo of the cohort divided by averaged serum intact PTH during the same period was examined in 34,307 MHD patients from all DaVita dialysis clinics across the United States using Cox regression. Results: MHD patients were 60.8 ± 15.4 yr of age and included 47% women, 34% black patients, and 47% patients with diabetes. Initially, the ratio of paricalcitol (μg/wk) to PTH (pg/ml) was divided into four groups: 0 (reference), 1 to −3. Unadjusted, case mix–adjusted (demographics, comorbidity, and Kt/V), and malnutrition-inflammation complex syndrome–adjusted models, the death rate ratio for the paricalcitol/PTH index groups, were 0.99, 0.95, and 0.92. Restricted cubic splines analyses were consistent with a linear relation. Conclusions: Higher weekly paricalcitol dosage per each unit of serum PTH seems to have an incremental association with greater survival in MHD patients. The observed dosage-response phenomenon needs to be confirmed in clinical trials.Keywords
This publication has 38 references indexed in Scilit:
- Serum and Dialysate Potassium Concentrations and Survival in Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2007
- Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patientsKidney International, 2006
- Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal studyKidney International, 2006
- Association between Serum Bicarbonate and Death in Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2006
- Editorials: Parathyroid Hormone Assay Drift: An Unappreciated Problem in Dialysis Patient ManagementSeminars in Dialysis, 2005
- VITAMIN D IN HEALTH AND DISEASE: Beyond Minerals and Parathyroid Hormone: Role of Active Vitamin D in End‐Stage Renal DiseaseSeminars in Dialysis, 2005
- VITAMIN D IN HEALTH AND DISEASE: Role of Parathyroid Hormone and Therapy with Active Vitamin D Sterols in Renal OsteodystrophySeminars in Dialysis, 2005
- Approaches to combat with confounding by indication in observational studies of intended drug effectsPharmacoepidemiology and Drug Safety, 2003
- Flexible regression models with cubic splinesStatistics in Medicine, 1989
- Reduced Binding of [3H]l,25-Dihydroxyvitamin D3in the Parathyroid Glands of Patients with Renal FailureNew England Journal of Medicine, 1987